ORCID as entered in ROS

Select Publications
2015, 'Fibrates: risk-benefits and role in treating dyslipidemias', in Dyslipidemias Pathophysiology, Evaluation and Management, Humana Press
,2011, 'Intensive glycemic control and renal outcome', in Diabetes and the Kidney, Karger Medical and Scientific Publishers
,2025, 'Trends in use of sodium-glucose cotransporter 2 inhibitors among people with type 2 diabetes following hospitalisation with heart failure: A population-based study', Diabetes Research and Clinical Practice, 224, pp. 112242, http://dx.doi.org/10.1016/j.diabres.2025.112242
,2025, 'Variability in HbA1c and the risk of major clinical outcomes in type 2 diabetes with chronic kidney disease: Post hoc analysis from the CREDENCE trial', Diabetes, Obesity and Metabolism, 27, pp. 3531 - 3535, http://dx.doi.org/10.1111/dom.16363
,2025, 'Assessing patterns of chronic kidney disease care in Australian primary care: a retrospective cohort study of a national general practice dataset', The Lancet Regional Health - Western Pacific, 57, http://dx.doi.org/10.1016/j.lanwpc.2025.101541
,2025, 'Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial', Diabetes, Obesity and Metabolism, 27, pp. 1972 - 1979, http://dx.doi.org/10.1111/dom.16190
,2025, 'Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD', Kidney International Reports, 10, pp. 1037 - 1049, http://dx.doi.org/10.1016/j.ekir.2025.01.029
,2025, 'Predicting Contrast-Associated Acute Kidney Injury', JAMA Network Open, 8, http://dx.doi.org/10.1001/jamanetworkopen.2025.0107
,2025, 'Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?', Diabetes, Obesity and Metabolism, 27, pp. 997 - 1000, http://dx.doi.org/10.1111/dom.16061
,2025, 'Prevalence and Treatment Patterns of Anaemia in Individuals With Chronic Kidney Disease Across Asia: A Systematic Review and Meta-Analysis', Nephrology, 30, http://dx.doi.org/10.1111/nep.70002
,2025, 'Commentary on the 2021 update of the KDIGO clinical practice guideline for management of blood pressure in chronic kidney disease', Nephrology, 30, http://dx.doi.org/10.1111/nep.14414
,2025, 'Safety and Effectiveness of Apixaban versus Warfarin by Kidney Function in Atrial Fibrillation', Kidney360, http://dx.doi.org/10.34067/KID.0000000809
,2024, 'Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes', Journal of the American College of Cardiology, 84, pp. 2246 - 2250, http://dx.doi.org/10.1016/j.jacc.2024.08.006
,2024, 'Australian and New Zealand Living Guideline cholesterol-lowering therapy for people with chronic kidney disease (CARI Guidelines): Reducing the evidence-practice gap', Nephrology, 29, pp. 495 - 509, http://dx.doi.org/10.1111/nep.14295
,2024, 'Risk of recurrent stroke and dementia following acute stroke by changes in kidney function: results from the Perindopril Protection Against Recurrent Stroke Study', Journal of Hypertension, 42, pp. 1313 - 1321, http://dx.doi.org/10.1097/HJH.0000000000003711
,2024, 'Consumer involvement in the development and dissemination of chronic kidney disease guidelines: a summary of a meaningful and sustainable approach developed by Caring for Australians and New ZealandeRs with kidney Impairment guidelines', Journal of Clinical Epidemiology, 170, http://dx.doi.org/10.1016/j.jclinepi.2024.111330
,2024, 'Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis', American Journal of Kidney Diseases, 83, pp. 350 - 359.e1, http://dx.doi.org/10.1053/j.ajkd.2023.07.023
,2024, 'Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data', The Lancet Regional Health - Western Pacific, 43, http://dx.doi.org/10.1016/j.lanwpc.2023.100988
,2024, 'The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset', Kidney International Reports, 9, pp. 312 - 322, http://dx.doi.org/10.1016/j.ekir.2023.11.022
,2024, 'Assessing the Quality of Care for People with CKD: A Systematic Review and Meta-Analysis', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.2024bzcfkb63
,2024, 'Cardiovascular, Kidney, and Safety Outcomes with Canagliflozin in Older Adults: A Pooled Secondary Analysis of the CANVAS Program and CREDENCE Trial', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.2024e59ygyz9
,2024, 'Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.', NEJM Evid, 3, pp. EVIDoa2300189, http://dx.doi.org/10.1056/EVIDoa2300189
,2024, 'Risk-Based Implementation of SGLT2 Inhibitors: Insights from the CANVAS Program and CREDENCE Trial', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.2024k6fn2ax5
,2024, 'Use of SGLT2 Inhibitors and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Australian Primary Care Patients with Type 2 Diabetes Mellitus (T2DM) Stratified by CKD Status', Journal of the American Society of Nephrology, 35, pp. 10.1681/asn.2024f7q40fk1, http://dx.doi.org/10.1681/asn.2024f7q40fk1
,2024, 'WCN24-2313 LONG-TERM SAFETY OF HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS IN CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS', Kidney International Reports, 9, pp. S562 - S563, http://dx.doi.org/10.1016/j.ekir.2024.02.1183
,2023, 'Antioxidants for adults with chronic kidney disease', Cochrane Database of Systematic Reviews, 2023, http://dx.doi.org/10.1002/14651858.CD008176.pub3
,2023, 'Duration and effectiveness of glucose-lowering regimens in the real world management of diabetes: Data from the Australian EXTEND45 Linked Cohort Study', Endocrine and Metabolic Science, 12, http://dx.doi.org/10.1016/j.endmts.2023.100135
,2023, 'Kidney function and the comparative effectiveness and safety of direct oral anticoagulants vs. warfarin in adults with atrial fibrillation: a multicenter observational study', European Heart Journal - Quality of Care and Clinical Outcomes, 9, pp. 621 - 631, http://dx.doi.org/10.1093/ehjqcco/qcac069
,2023, 'Short report: Factors contributing to young people's susceptibility to e-cigarettes in four countries', Drug and Alcohol Dependence, 250, http://dx.doi.org/10.1016/j.drugalcdep.2023.109944
,2023, 'Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials', Journal of the American Heart Association, 12, pp. e028516, http://dx.doi.org/10.1161/JAHA.122.028516
,2023, 'Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada', Kidney Medicine, 5, http://dx.doi.org/10.1016/j.xkme.2023.100675
,2023, 'Clinical outcomes by atherosclerotic cardiovascular disease risk score and blood pressure level in high risk individuals with type 2 diabetes', Journal of Human Hypertension, 37, pp. 181 - 188, http://dx.doi.org/10.1038/s41371-022-00661-5
,2023, 'E-cigarettes: A continuing public health challenge in India despite comprehensive bans', Preventive Medicine Reports, 31, http://dx.doi.org/10.1016/j.pmedr.2022.102108
,2023, 'Characterization of Risk Prediction Models for Acute Kidney Injury A Systematic Review and Meta-analysis', JAMA Network Open, 6, http://dx.doi.org/10.1001/jamanetworkopen.2023.13359
,2023, 'Comparing survival in patients with chronic kidney disease across three countries – Results from the study of heart and renal protection-extended review', Nephrology, 28, pp. 36 - 43, http://dx.doi.org/10.1111/nep.14127
,2023, 'Long-Term Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in CKD: A Systematic Review and Meta-Analysis of Randomized Trials', Journal of the American Society of Nephrology, 34, pp. 367 - 367, http://dx.doi.org/10.1681/asn.20233411s1367a
,2023, 'The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset', Journal of the American Society of Nephrology, 34, pp. 373 - 373, http://dx.doi.org/10.1681/asn.20233411s1373a
,2023, 'WCN23-0200 PREVALENCE AND TREATMENT PATTERNS OF ANAEMIA IN INDIVIDUALS WITH CHRONIC KIDNEY DISEASE ACROSS ASIA', Kidney International Reports, 8, pp. S135 - S136, http://dx.doi.org/10.1016/j.ekir.2023.02.309
,2022, 'Young people's support for various forms of e-cigarette regulation in Australia and the UK', International Journal of Drug Policy, 110, http://dx.doi.org/10.1016/j.drugpo.2022.103858
,2022, 'School staff perceptions of the nature and consequences of students’ use of e-cigarettes', Australian and New Zealand Journal of Public Health, 46, pp. 676 - 681, http://dx.doi.org/10.1111/1753-6405.13281
,2022, 'Commentary on the 2020 update of the KDOQI clinical practice guideline for nutrition in chronic kidney disease', Nephrology, 27, pp. 537 - 540, http://dx.doi.org/10.1111/nep.14025
,2022, 'Sex differences in chronic kidney disease prevalence in Asia: A systematic review and meta-analysis', Clinical Kidney Journal, 15, pp. 1144 - 1151, http://dx.doi.org/10.1093/ckj/sfac030
,2022, 'Risk factors for incident kidney disease in older adults: an Australian prospective population-based study', Internal Medicine Journal, 52, pp. 808 - 817, http://dx.doi.org/10.1111/imj.15074
,2022, 'Prior Cardiovascular Treatments—A Key Characteristic in Determining Medication Adherence After an Acute Myocardial Infarction', Frontiers in Pharmacology, 13, http://dx.doi.org/10.3389/fphar.2022.834898
,2022, 'The impact of tightened prescribing restrictions on proton pump inhibitor use in Australia: An evaluation using interrupted time series analysis', Pharmacoepidemiology and Drug Safety, 31, pp. 370 - 378, http://dx.doi.org/10.1002/pds.5395
,2022, 'A cluster randomized controlled trial of a MedicineInsight Educational Quality Improvement Programme to improve the diagnosis and treatment of chronic hepatitis C in general practice (the EQUIP-HEPC trial)', Journal of Viral Hepatitis, 29, pp. 135 - 146, http://dx.doi.org/10.1111/jvh.13629
,2022, 'Prevalence of chronic kidney disease in Asia: A systematic review and analysis', BMJ Global Health, 7, pp. e007525, http://dx.doi.org/10.1136/bmjgh-2021-007525
,2022, 'Abstract P201: Canagliflozin, Visit-to-visit Blood Pressure Variability, And Risk Of Cardiovascular, Kidney, And Mortality Outcomes: Pooled Individual Participant Data From The CANVAS And CREDENCE Trials', Hypertension, 79, http://dx.doi.org/10.1161/hyp.79.suppl_1.p201
,2022, 'Lower Glomerular Filtration Rate and Higher Albuminuria Are Associated With Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis', Journal of the American Society of Nephrology, 33, pp. 297 - 298, http://dx.doi.org/10.1681/asn.20223311s1297c
,2022, 'Robotic deep inferior epigastric perforator flap harvest in breast reconstruction', MICROSURGERY, 42, pp. 319 - 325, http://dx.doi.org/10.1002/micr.30856
,